Bio-Techne Corporation and Arrowhead Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis

Biotech Giants: A Decade of Growth and Innovation

__timestampArrowhead Pharmaceuticals, Inc.Bio-Techne Corporation
Wednesday, January 1, 2014175000251411000
Thursday, January 1, 2015382000307277000
Friday, January 1, 2016158333336659000
Sunday, January 1, 201731407709374541000
Monday, January 1, 201816142321432143000
Tuesday, January 1, 2019168795577473491000
Wednesday, January 1, 202087992066483194000
Friday, January 1, 2021138287000632850000
Saturday, January 1, 2022232810000756496000
Sunday, January 1, 2023240735000769815000
Monday, January 1, 20243551000769725000
Loading chart...

In pursuit of knowledge

A Tale of Two Innovators: Bio-Techne and Arrowhead Pharmaceuticals

In the dynamic world of biotechnology, Bio-Techne Corporation and Arrowhead Pharmaceuticals, Inc. have carved distinct paths over the past decade. From 2014 to 2023, Bio-Techne's gross profit surged by over 200%, peaking at approximately $770 million in 2023. This growth underscores its robust market position and innovative prowess. In contrast, Arrowhead Pharmaceuticals, while starting with a modest gross profit of around $175,000 in 2014, experienced a meteoric rise, achieving a staggering 137,000% increase by 2023. This remarkable growth trajectory highlights Arrowhead's strategic advancements in RNA interference therapeutics. Despite the absence of 2024 data, these trends reflect the companies' resilience and adaptability in a competitive landscape. As the biotech sector continues to evolve, these two companies exemplify the potential for innovation-driven success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025